NT-proBNP 对评估 COPD 急性加重风险的意义简

目的 主要探讨检测血浆N端脑钠肽前体（NT-proBNP）对评估慢性阻塞性肺疾病（COPD）急性加重风险的意义.方法 选取2012.1~2012.8 在我院住院治疗的COPD患者63名,根据2011版GOLD策略综合评估分为COPD低危组22人（包含A组和B组）和COPD高危组23人（包含C组和D组）,分别测定并比较2组NT-proBNP、肺功能、体重指数及并发症情况.结果 COPD低危组患者血浆NT-proBNP水平（245.7±166.2 pg/ml）明显低于COPD高危组患者（1326.7±198.8 pg/ml）（P〈0.05）.肺功能FEV1（perd%）与NT-proBNP（pg/ml）成负相关（r=-0.395,P=0.001）.而年龄、性别与体重指数则与NT-proBNP（pg/ml）无相关性（P＞0.05）.结论 NT-proBNP能较好反应COPD的急性加重风险.

Value of NT-proBNP in the evaluation of patients with chronic obstructive pulmonary disease

Objective To investigate the value of NT-proBNP in the evaluation of patients with AECOPD. Methods 63 AECOPD patients were divided into the low-risk group （including the group A and B） and the high- risk group （including the group C and D ） based on a comprehensive assessment according to GOLD. The low-risk group contained 31 patients and the high -risk group contained 32 patients. Their NT-proBNP, lung function, body mass index （BMI） and complications were measured. Results The level of NT-proBNP was 245.7 ± 166. 2 pg/ml in the low risk group, which was much lower than that in the high-risk grot,p （ 1326. 7 ± 198.8 pg/ml ） （ P 〈 0. 05 ）. FEVI were negatively related with tile level of NT-proBNP, While the age, sex and BMI had no relationship with the level of NT-proBNP. Conclusion The measurcmenl of NT-proBNP can belier reileet the risk of AECOPD patients.